Should a lumpectomy cavity boost be given to cN0 patients who receive neo-adjuvant chemotherapy and have a path CR, if planning to complete hypofractionated whole breast radiation?

There is no prospective or retrospective data in this setting but we routinely boost this patients, as usually NACT is used for triple negative, Her2-neu positive, or higher T disease and thus, the rationale for the boost.

Once you have recommended post-lumpectomy radiation (and today there are no data to support omission of whole breast after pCR), this question of boost is- are the potential residual cells that you are trying to eradicate more radiosenstive so eradicated by lower dose? There are truly no data on thi...